Clinical trials: Ovarian Tumor
Ovarian Cancer, Fallopian Tube Cancer
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- SIGNAL (NCT04368130)
- Testing
- SIGNAL
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
High Grade Serous Carcinoma
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant).
- Trial name
- CAPRI (NCT03462342)
- Testing
- Olaparib Pill, AZD6738
- Where
- 3 sites in United States
- Volunteers
- 123 people
- Sponsor
- University of Pennsylvania
Carcinoma of the Ovary, Fallopian Tube Cancer
Search for Predictors of Therapeutic Response in Ovarian Carcinoma
In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA…
- Conditions
- Carcinoma of the Ovary, Fallopian Tube Cancer, Peritoneal Serous-type Advanced Stage
- Trial name
- miRSa (NCT01391351)
- Testing
- blood samples
- Where
- 7 sites in France
- Volunteers
- 107 people
- Sponsor
- Centre Francois Baclesse
Ovarian Cancer, Fallopian Tube Neoplasms
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
The purpose of this study is to use an immunologic approach following the treatment for recurrent disease in patients with ovarian, fallopian tube, or peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00103545
- Testing
- ACA 125
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- AGO Study Group
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Medical Education, Ovarian Cancer
Ultrasound Training Program for Gynecologic Cancer Staging in Residents
This is a prospective, interventional study aiming to develop and validate an ultrasound training program for gynecology and obstetrics residents, focused on the staging of gynecologic cancers, including ovarian, endometrial, and…
- Conditions
- Medical Education, Ovarian Cancer, Endometrial Cancer, Cervix Cancer
- Trial name
- Ultra-teaching (NCT07028229)
- Testing
- Training Group
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Adult Angiosarcoma, Adult Epithelioid Sarcoma
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma.
- Conditions
- Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00245102
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Solid Tumours, Metastatic Solid Tumours
Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
This Phase Ib study will identify the Maximum Tolerated Dose (MTD) of AZD1775 monotherapy when administered orally once daily (QD) or two times per day (BID) on Days 1 to 5 followed by 9 days of rest in 14-day cycles, or QD on a…
- Conditions
- Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
- Trial name
- NCT02610075
- Testing
- AZD1775
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Breast Cancer, Ovarian Epithelial Cancer Recurrent
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
This is a study to assess the safety of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors, and determine preliminary efficacy of the…
- Conditions
- Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02014337
- Testing
- Mifepristone and Eribulin in combination
- Where
- 11 sites in United States
- Volunteers
- 37 people
- Sponsor
- Corcept Therapeutics
Polycystic Ovary Syndrome, Estro-progestin Drugs
Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.
The estrogenic component of estro-progestin (EP) is responsible for a negative impact on the metabolic and lipid assessment in women with polycystic ovary syndrome (PCOS).
- Trial name
- NCT01519401
- Testing
- 3 mg drospirenone and 20 µg ethinyl-estradiol, 3 mg drospirenone and 30 µg ethinyl-estradiol
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Ovarian Neoplasms
Biobehavioral-Cytokine Interactions in Ovarian Cancer
The purpose of this study is to understand relationships between behavioral factors, hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer.
- Trial name
- VEGF (NCT01113112)
- Where
- 2 sites in United States
- Volunteers
- 613 people
- Sponsor
- Susan Lutgendorf
Body Weight, Polycystic Ovary Syndrome
The Effect of Obesity on Endometrium in PCOS
The effect of Polycystic Ovary Syndrome (PCOS) with or without obesity has received a few attentions. There is a lack of evidence to whether the BMI affects the endometrial blood flow, which is necessary for implantation.
- Trial name
- OB-PCO (NCT02694419)
- Testing
- Doppler evaluation
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Breast Cancer, Lung Cancer
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor…
- Conditions
- Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer
- Trial name
- TRT-001 (NCT02960594)
- Testing
- INO-1400, INO-9012, INO-1401
- Where
- 6 sites in United States
- Volunteers
- 93 people
- Sponsor
- Inovio Pharmaceuticals
Solid Tumors (Phase 1), Mesothelioma
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one.
- Conditions
- Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma, Ovarian Cancer
- Trial name
- AROG4-01-01 (NCT06652529)
- Testing
- AROG4-01
- Volunteers
- 35 people
- Sponsor
- Aromics Therapeutics
Ovarian Cancer, Primary Peritoneal Cancer
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment.
- Trial name
- NCT00928642
- Testing
- imatinib mesylate by mouth, Gemcitabine Intravenous
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
PI3K Pathway Activated Tumors
BKM120 for Patients With PI3K-activated Tumors
The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
- Trial name
- SIGNATURE (NCT01833169)
- Testing
- BKM120
- Where
- 59 sites in United States
- Volunteers
- 146 people
- Sponsor
- Novartis Pharmaceuticals
Polycystic Ovary Syndrome
Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment
The aim of this double-blinded, three-armed randomized controlled trial (RCT) is to evaluate the effects of a 6 months treatment with inositol alone or inositol associated with alpha-lipoic acid in women with polycystic ovary…
- Trial name
- IALA (NCT04881851)
- Testing
- Inositol + alpha lipoic acid, Inositol
- Where
- Italy
- Volunteers
- 76 people
- Sponsor
- Universita di Verona
Fallopian Tube Cancer, Ovarian Cancer
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004012
- Testing
- capecitabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycystic Ovary Syndrome
Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study
To investigate the effect of metformin on pregnancy complications and pregnancy outcome in the II. and III. trimester of pregnancy in women with polycystic ovary syndrome.
- Trial name
- pilPregMet (NCT03259919)
- Testing
- Metformin
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Norwegian University of Science and Technology
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.